Nouscom

Nouscom AG is a private, clinical-stage immuno-oncology company developing next-generation neoantigen-targeted cancer immunotherapies, founded in 2015 by Riccardo Cortese and Alfredo Nicosia, with headquarters in Basel, Switzerland and research and manufacturing operations in Rome, Italy. Its proprietary viral vector platform — great ape adenovirus and MVA vectors able to encode large neoantigen payloads together with other immunomodulators — is used to build both off-the-shelf and personalized cancer vaccines. The lead program, NOUS-209, targets 209 shared frameshift neoantigens for cancer interception in Lynch Syndrome carriers and for the treatment of dMMR/MSI metastatic colorectal cancer in combination with pembrolizumab; its second clinical program, NOUS-PEV, is a personalized immunotherapy for advanced solid tumors. Nouscom raised an oversubscribed EUR 67.5 million Series C in November 2023, co-led by Andera Partners, Bpifrance (InnoBio 2) and M Ventures. Nouscom is a therapeutics developer, not a software vendor: it publishes no public API, developer portal, SDK or machine-readable API contract, and is profiled here as an identity-only record.

Nouscom is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Immuno-Oncology, Pharmaceuticals, and Life Sciences.

🌐 Visit website 📡 Source on GitHub

4.0/100 minimal ▬ flat Agent 3/100 human only Full breakdown ↓
scored 2026-09-01 · rubric v0.17.2

0 APIs

Company Biotechnology Immuno-Oncology Pharmaceuticals Life Sciences Clinical Trials Cancer Immunotherapy Switzerland Italy Private Company

Kin Score

Kin Score How this is scored →
scored 2026-09-01 · rubric v0.17.2

Composite quality — 4.0/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 0.0 / 17

Operational Transparency 0.3 / 11

Contract Governance 0.0 / 10

Discoverability 4.6 / 9

Regulatory Posture 1.1 / 15

Agent readiness — 3/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 4 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Delegated User Identity 0 / 6

Protected Resource Metadata 0 / 5

Registration Without a Human 0 / 6

Agentic Commerce Surface 0 / 5

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/nouscom: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Build 1

SDKs, sample code, and the tooling you integrate with

GitHubOrganization

GitHubOrganization

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Company 2

The organization behind the API

Website

Website

LinkedIn

Source (apis.yml)

aid: nouscom
name: Nouscom
description: 'Nouscom AG is a private, clinical-stage immuno-oncology company developing next-generation neoantigen-targeted
  cancer immunotherapies, founded in 2015 by Riccardo Cortese and Alfredo Nicosia, with headquarters in Basel, Switzerland
  and research and manufacturing operations in Rome, Italy. Its proprietary viral vector platform — great ape adenovirus and
  MVA vectors able to encode large neoantigen payloads together with other immunomodulators — is used to build both off-the-shelf
  and personalized cancer vaccines. The lead program, NOUS-209, targets 209 shared frameshift neoantigens for cancer interception
  in Lynch Syndrome carriers and for the treatment of dMMR/MSI metastatic colorectal cancer in combination with pembrolizumab;
  its second clinical program, NOUS-PEV, is a personalized immunotherapy for advanced solid tumors. Nouscom raised an oversubscribed
  EUR 67.5 million Series C in November 2023, co-led by Andera Partners, Bpifrance (InnoBio 2) and M Ventures. Nouscom is
  a therapeutics developer, not a software vendor: it publishes no public API, developer portal, SDK or machine-readable API
  contract, and is profiled here as an identity-only record.'
url: https://raw.githubusercontent.com/api-evangelist/nouscom/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: identity
x-tier-reason: no-api-surface
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
specificationVersion: '0.20'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Biotechnology
- Immuno-Oncology
- Pharmaceuticals
- Life Sciences
- Clinical Trials
- Cancer Immunotherapy
- Switzerland
- Italy
- Private Company
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/nouscom-domain-security.yml
- type: LLMsTxt
  url: llms/nouscom-llms.txt
- type: Website
  url: https://nouscom.com/
- type: GitHubOrganization
  url: https://github.com/Nouscom
- type: LinkedIn
  url: https://www.linkedin.com/company/nouscom-ag/
x-enrichment:
  date: '2026-08-26'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Nouscom AG is a clinical-stage biotech whose product is a cancer immunotherapy, not software — it has no API host
    at all (api./dev./developer./docs./portal.nouscom.com are NXDOMAIN), its only public repository is R analysis code for
    the NOUS-209 Lynch Syndrome study, and its corporate WordPress site sits behind a SiteGround robot challenge that answers
    HTTP 202 to every path including /openapi.json.
  evidence:
  - url: https://api.nouscom.com/openapi.json
    status: 0
  - url: https://nouscom.com/openapi.json
    status: 202
  - url: https://nouscom.com/.well-known/agent-card.json
    status: 202
  - url: https://github.com/Nouscom
    status: 200
  checked: '2026-08-26'

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this

find_providersBrowse and filter every provider in the catalog.
get_provider_artifactsEvery artifact this provider publishes, grouped by type.
get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
get_provider_ratingPRO — composite, band, trend and facet scores.
apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
resolveTurn a domain, URL or GitHub org into the provider it belongs to.
find_cohortsEvery scored population of providers in the catalog.

All 92 tools →

Call it yourself

curl for this page

This provider

curl "https://apis.io/api/v1/providers/nouscom"

All providers

curl "https://apis.io/api/v1/providers?limit=25"

Every operation they expose

curl "https://apis.io/api/v1/providers/nouscom/operations?limit=25"

How their score was established

curl "https://apis.io/api/v1/providers/nouscom/evidence"

Discovery needs no key. Ratings and market analysis are Pro.

Get an API key

Free tier, no email required.

GitHub Google LinkedIn

A second provider on the same verified email joins the account you already have.